Solutions
Access to Medicine
Social Impact in Life Sciences: broadening Access to Medicine for patients
The pharmaceutical industry is transitioning toward a more sustainable and inclusive model, where health equity and social impact are becoming a growing component of value creation. Significant industry progress on ESG has been made already and is accelerating, with pharmaceutical companies focusing efforts on expanding access to their products and solutions: a pharma-specific topic that requires to rethink the existing access paradigm.
A momentum for the life sciences industry to act
In the health ecosystem, life sciences companies are recognized by all stakeholders to play a critical role in addressing health inequities, through their direct and indirect impacts on individual and community health.
We support life sciences companies as they embark on their journey towards a more inclusive model
Why Deloitte?
Our experts
Stéphane Bazoche
Partner, Head of the Life Sciences and Healthcare practice
Sur le même sujet
Vision for the future of Access to Medicine
Contributing to social value creation by pharmaceutical industries for sustainable growth
